PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31297844-7	2019	In the presence of enzalutamide, apoptosis occurred which was shown by increased BAX expression, decreased Bcl-2 expression, nuclear pyknosis, and genomic DNA fragmentation.	enzalutamide	19-31	BCL2 apoptosis regulator	Homo sapiens	107-112	
31228231-0	2019	Targeting prosurvival BCL2 signaling through Akt blockade sensitizes castration-resistant prostate cancer cells to enzalutamide.	enzalutamide	115-127	BCL2 apoptosis regulator	Homo sapiens	22-26	
31228231-8	2019	RESULTS: In the present study, we identify antiapoptotic BCL2 protein signaling as a mechanism of resistance to AR antagonist enzalutamide.	enzalutamide	126-138	BCL2 apoptosis regulator	Homo sapiens	57-61	
35405009-6	2022	Accordingly, treatment with CDK4/6 and BCL2 inhibitors sensitized PRRX2-expressing, castration-resistant tumors to enzalutamide.	enzalutamide	115-127	BCL2 apoptosis regulator	Homo sapiens	39-43	
35579133-12	2022	Moreover, enzalutamide downregulated the expression of the anti-apoptosis genes, mcl1 and bcl2, in MDA-MB-231 cells.	enzalutamide	10-22	BCL2 apoptosis regulator	Homo sapiens	90-94	
35579133-16	2022	On the other hand, enzalutamide may sensitize the cells to doxorubicin through downregulation of the bid/bcl2/mcl1 axis that normally activates the executive caspases, caspase 3/7.	enzalutamide	19-31	BCL2 apoptosis regulator	Homo sapiens	105-109	
32782617-7	2020	Western blotting results indicated that enzalutamide treatment downregulated the expression levels of JNK and activated transcription factor 2, as well as enhanced the Bax/Bcl-2 ratio and induced cleavage of poly-ADP ribose polymerase.	enzalutamide	40-52	BCL2 apoptosis regulator	Homo sapiens	172-177	
33542074-0	2021	Emergence of Enzalutamide resistance in prostate cancer is associated with BCL-2 and IKKB dependencies.	enzalutamide	13-25	BCL2 apoptosis regulator	Homo sapiens	75-80	
33542074-7	2021	Notably, we observed that overexpression of BCL-2 and IKKB in ENZ-sensitive cell lines was sufficient for the emergence of ENZ resistance.	enzalutamide	62-65	BCL2 apoptosis regulator	Homo sapiens	44-49